Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 885

Sort by

Sort Order Select

Journal Articles

One step at a time

Hélène Schoemans, Per Ljungman

Blood (2021) 138 (14): 1208–1209.

https://doi.org/10.1182/blood.2021013434

Published: 2021

Journal Articles

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Blood (2021) 138 (9): 811–814.

https://doi.org/10.1182/blood.2021012443

Published: 2021

Includes: Supplemental data

Journal Articles

Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance

Carlijn Voermans, Mette D. Hazenberg

Blood (2020) 136 (4): 410–417.

https://doi.org/10.1182/blood.2019000951

Published: 2020

Journal Articles

Introduction to a review series on pathophysiology and treatment of acute GVHD

Robert Zeiser

Blood (2020) 136 (4): 375–376.

https://doi.org/10.1182/blood.2019004271

Published: 2020

Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3887.

https://doi.org/10.1182/blood-2019-128506

Published: 2019

Journal Articles

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Hong Mu-Mosley, MD PhD, Lauren B Ostermann, Muharrem Muftuoglu, MD, Wendy Schober, Nalini B Patel, Abishek Vaidya, MS, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3917.

https://doi.org/10.1182/blood-2019-125928

Published: 2019

Journal Articles

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Cesar Sommer, PhD, Hsin-Yuan Cheng, PhD, Yik Andy Yeung, PhD, Duy Nguyen, Janette Sutton, Zea Melton, Julien Valton, PhD, Kris Poulsen, Ivana Djuretic, PhD, Thomas Van Blarcom, PhD, Javier Chaparro-Riggers, PhD, Barbra Sasu, PhD

Blood (2019) 134 (Supplement_1): 3921.

https://doi.org/10.1182/blood-2019-129025

Published: 2019

Journal Articles

Nicotinamide (NAM) Modulates Transcriptional Signature of Ex Vivo Cultured UCB CD34+ Cells (Omidubicel) and Preserves Their Stemness and Engraftment Potential

Tracey Lodie, PhD, Julian Adams, PhD, Dima Yackoubov, Msc, Yair Steinhardt, MSc, Dorit Ashengrau, Adi Bitansky, Alina Maliutina, Sherry Cohen, Boaz Buhenvald, PhD, Moshe Shahor, PhD, Nathan Dinowitz, PhD, Vered Caspi, PhD, Amnon Peled, PhD, Tony Peled, MSc

Blood (2019) 134 (Supplement_1): 3718.

https://doi.org/10.1182/blood-2019-131124

Published: 2019

Journal Articles

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Caspian Oliai, MD, Sven de Vos, MD PhD

Blood (2019) 134 (Supplement_1): 5360.

https://doi.org/10.1182/blood-2019-129371

Published: 2019

Journal Articles

The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets

Edward Truelove, MBBS, BSc, MRCP, FRCPath, Frances Seymour, MRCP, BSc, MBBS, Joseph G Taylor, MBBS, BSc, Mariarita Calaminici, Andrew James Clear, BSc, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 5240.

https://doi.org/10.1182/blood-2019-130712

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

Journal Articles

AVM0703, a New Treatment Option for Lymphoma Patients

Theresa Deisher, PhD, Margaret Taylor, Arya Ashok, PhD, Peter Jarzyna, PhD, Yumna Zahid, Stephanie Lee-Diaz, Colleen Rylatt, Kendra Poulin, Vaishnavi Parthasarathy

Blood (2019) 134 (Supplement_1): 5308.

https://doi.org/10.1182/blood-2019-128812

Published: 2019

Journal Articles

Relative Depletion of Soluble Interleukin 6 Receptors Abolished the Development of Cytokine Release Syndrome after CART19/22 and Lenalidomide Treatment for Lymphoma

Caixia Li, Changfeng Zhang, PhD, Xiaochen Chen, Ying Zhang, Jia Chen, MD, Liqing Kang, Xiaoyan Lou, Jin Zhou, Xiangping Zong, Zhen Yang, Jiaqi Li, Wei Qi, Lei Yu, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 5313.

https://doi.org/10.1182/blood-2019-126821

Published: 2019

Journal Articles

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Sabrina L Browning, MD, Terri L Parker, MD, Noffar Bar, MD, Stuart Seropian, MD, Alfred I Lee, MD PhD, Tara Anderson, PA, Natalia Neparidze, MD

Blood (2019) 134 (Supplement_1): 5569.

https://doi.org/10.1182/blood-2019-130134

Published: 2019

Journal Articles

Evolving Data on CAR T-Cell Therapy for Multiple Myeloma, Novel Targets, Conditioning Regimens and Novel Constructs: A Systematic Review

Yusra Shao, MD, Daniel S Carlson, DO, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5547.

https://doi.org/10.1182/blood-2019-122292

Published: 2019

Journal Articles

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease

Cindy Varga, MD BSc, Viji Nair, PhD, Agnes Fogo, MD, Samih Nasr, MD, Bradley Godfrey, PhD, Felix Eichinge, PhD, Denis Toskic, BS, Matthias Kretzler, MD, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 5500.

https://doi.org/10.1182/blood-2019-123228

Published: 2019

Journal Articles

Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy

Shuangshuang Yang, MD, Lijuan Chen, MD PhD, Jie Xu, MD PhD, Frank Xiao-Hu Fan, MD PhD, Sun Yan, PhD, Wen Wu, MD PhD, Yan Wang, MD, Jin Wang, MD PhD, Shiwei Jin, MD, Yuebo Zhou, Yuanfang Liu, MD PhD, Yan Zhuang, PhD, Wu Zhang, PhD, Jun-Min Li, Jian Hou, PhD MD, Jian-Yong Li, MD PhD, Zhu Chen, PhD, Jian-Qing Mi, MD PhD, Sai-Juan Chen, PhD

Blood (2019) 134 (Supplement_1): 5617.

https://doi.org/10.1182/blood-2019-131799

Published: 2019

Journal Articles

Modeling of Immune Reconstitution Post CD34 Selected Stem Cell Transplantation in Pediatric Patients with Severe Combined Immune Deficiency

Jean-Sebastien Diana, MD, Naim Bouazza, PhD, Chloé Couzin, MD, Martin Castelle, MD, Alessandra Magnani, MD PhD, Elisa Magrin, PhD, Laure Joseph, MD, Marianne Delville, MD, Francois Lefrere, MD, jean-Marc Treluyer, MD PhD, Capucine Picard, MD PhD, Despina Moshous, MD PhD, Isabelle André, PhD, Stephane Blanche, MD, Benedicte Neven, MD PhD, Marina Cavazzana, MD PhD

Blood (2019) 134 (Supplement_1): 5668.

https://doi.org/10.1182/blood-2019-127974

Published: 2019

Journal Articles

Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL

Ping Li, Lili Zhou, Shiguang Ye, Shaoguang Li, Aibin Liang, MD PhD

Blood (2019) 134 (Supplement_1): 5625.

https://doi.org/10.1182/blood-2019-130119

Published: 2019

Journal Articles

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Sepideh Mokhtari, MD, Justin M Asquith, MD, Christina A Bachmeier, PharmD, Michael D. Jain, MD PhD, Peter Forsyth, MD, Frederick L. Locke, MD, Youngchul Kim, PhD, Aleksandr Lazaryan, MD PhD MPH

Blood (2019) 134 (Supplement_1): 5627.

https://doi.org/10.1182/blood-2019-122343

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

One step at a time

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance

Introduction to a review series on pathophysiology and treatment of acute GVHD

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Nicotinamide (NAM) Modulates Transcriptional Signature of Ex Vivo Cultured UCB CD34+ Cells (Omidubicel) and Preserves Their Stemness and Engraftment Potential

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

AVM0703, a New Treatment Option for Lymphoma Patients

Relative Depletion of Soluble Interleukin 6 Receptors Abolished the Development of Cytokine Release Syndrome after CART19/22 and Lenalidomide Treatment for Lymphoma

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Evolving Data on CAR T-Cell Therapy for Multiple Myeloma, Novel Targets, Conditioning Regimens and Novel Constructs: A Systematic Review

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease

Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy

Modeling of Immune Reconstitution Post CD34 Selected Stem Cell Transplantation in Pediatric Patients with Severe Combined Immune Deficiency

Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only